Poly medicure Limited has announced a scheduled one-on-one investor meeting with Avendus Spark, demonstrating the company's commitment to maintaining transparent investor relations and regulatory compliance.

Meeting Details

The company has formally notified both BSE and NSE about the upcoming investor engagement scheduled for March 19, 2026. The meeting will be conducted in a virtual format, reflecting modern business practices and accessibility considerations.

Regulatory Compliance

Poly Medicure Limited has issued this intimation pursuant to Regulation 30 and applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has emphasized its commitment to regulatory transparency by formally notifying the stock exchanges about this scheduled investor interaction.

The company has specifically stated that no unpublished price sensitive information will be shared during the meeting, ensuring compliance with insider trading regulations and maintaining market integrity.

Schedule Flexibility

The company has noted that the meeting schedule remains subject to potential changes due to exigencies that may arise from the analysts, investors, or the company itself. This flexibility clause demonstrates practical business considerations while maintaining professional commitment to investor engagement.

The meeting information has been made available on the company's official website at www.polymedicure.com , ensuring broader accessibility for stakeholders and maintaining transparency standards.

Corporate Communication

The formal communication to stock exchanges was signed by Avinash Chandra, Company Secretary (M. No. A32270), on March 12, 2026, demonstrating proper corporate governance procedures and timely disclosure practices.

Poly Medicure has shared an updated investor presentation with the BSE and NSE, making it accessible to stakeholders through the company's official website. The presentation provides comprehensive insights into the company's current operational capabilities and manufacturing infrastructure.

Manufacturing Infrastructure

The updated presentation highlights Poly Medicure's substantial manufacturing footprint across the medical devices sector. The company's operational scale demonstrates its significant presence in the industry.

Investor Communication

The company has ensured transparency by filing the updated presentation with both major stock exchanges and making it readily available to investors and stakeholders through its website. This move reflects the company's commitment to keeping stakeholders informed about its operational capabilities and business scale.

The presentation serves as a comprehensive resource for investors seeking detailed information about Poly Medicure's manufacturing capabilities and production capacity in the medical devices segment.